Dimensional Fund Advisors’s First Tracks Biotherapeutics TRAX Stock Holding History

Dimensional Fund Advisors’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15M	Buy	+57,064	New	+$1.07M	﹤0.01%	2838

Other funds holding TRAX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

FEG

Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Dimensional Fund Advisors's TRAX Position: Q2 2026 in Review

Dimensional Fund Advisors opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 57,064 shares worth $1.15M. The stake represents ﹤0.01% of the portfolio and ranks #2838 among its holdings.

51 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

Dimensional Fund Advisors held 57,064 shares of First Tracks Biotherapeutics worth $1.15M as of Q2 2026.
First Tracks Biotherapeutics was a new Dimensional Fund Advisors position in Q2 2026.
First Tracks Biotherapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2838 holding.
51 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.